AIDS TREATMENT NEWS No. 061 - July 29, 1988
John S. James
The 14 patients started the treatment in 1985 and 1986. 12 have shown clear and often major clinical improvement -- including those who had had pneumocystis once or more before beginning. (Of the other two, one left the study in 1986 and died a year later; the second, an IV drug user who also has hepatitis B, is still alive although his condition has worsened since he started the trial in June of 1986.)
Comment
The treatment consists of a heat-treated, killed-virus vac- cine prepared from each patient's own blood. This approach overcomes the usual vaccine problem of the great variation among different strains of HIV. A vaccine prepared for one strain usually will not work for others; but here the patient's own strain is used.
Autovaccination also eliminates the worry of reinfection with a different strain in case some of the virus should survive the heat treatment.
But how could it help to inoculate the patient with antigens which he or she already has? The answer may be that the AIDS virus subverts the process by which the body normally produces antibodies, causing it to produce more virus instead. But the killed virus cannot infect the T-helper cells, so it might allow the body's normal defenses to work, even when they could not work against the live virus.
For More Information
For more information about autovaccination as an AIDS/ARC treatment, see the letter by H. Bruster and others, The Lancet, June 4, 1988, pages 1284-1285. Most of the other information now available -- referenced in that letter -- has been published only in German.
880729
ATN06103
Copyright © 1988 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .